The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease
Introduction. Enzyme-linked immunosorbent assay of biochemical markers is one of the most important methods for diagnosing tumors. One of these markers is an inducer of expression of matrix metalloproteases EMMPRIN/CD147. Changes in its expression are associated with the progression of some tumors....
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-07-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/545 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025244749725696 |
|---|---|
| author | N. E. Kushlinskii O. V. Kovaleva Yu. B. Kuzmin E. V. Samoilova P. L. Prishchep E. S. Gershtein S. R. Varfolomeeva D. V. Rogozhin N. Yu. Sokolov K. A. Borzov E. A. Sushentsov A. K. Valiev I. S. Stilidy |
| author_facet | N. E. Kushlinskii O. V. Kovaleva Yu. B. Kuzmin E. V. Samoilova P. L. Prishchep E. S. Gershtein S. R. Varfolomeeva D. V. Rogozhin N. Yu. Sokolov K. A. Borzov E. A. Sushentsov A. K. Valiev I. S. Stilidy |
| author_sort | N. E. Kushlinskii |
| collection | DOAJ |
| description | Introduction. Enzyme-linked immunosorbent assay of biochemical markers is one of the most important methods for diagnosing tumors. One of these markers is an inducer of expression of matrix metalloproteases EMMPRIN/CD147. Changes in its expression are associated with the progression of some tumors. This study is the first work devoted to the study of the content of the soluble form of the transmembrane glycoprotein EMMPRIN (sEMMPRIN) in the blood serum of patients with various bone tumors.Aim. To study the content of sEMMPRIN in the blood serum of patients with malignant bone tumors, its relationship with the clinical and morphological characteristics of neoplasms and prognosis.Materials and methods. The study included 88 patients with malignant tumors (osteosarcoma – 37 cases, chondrosarcoma – 39, chordoma – 5, Ewing’s sarcoma – 7) and borderline (11 cases) bone neoplasms, of which 14 patients were under the age of 18 years. The control group consisted of 29 healthy donors, 8 of which were under the age of 18 years. The concentration of EMMPRIN was determined in the serum of patients and donors with reagents for direct enzyme immunoassay “Human EMMPRIN” (R&D, USA) in accordance with the manufacturer’s instructions and expressed in nanograms (ng) per 1 ml of blood serum. The obtained data were processed using the GraphPad Prizm 9.4 program. When comparing indicators and analyzing their relationships, we used the nonparametric Mann–Whitney and Kruskal–Wallis tests. Overall survival was analyzed using the Kaplan–Meier method.Results. Our analysis of the sEMMPRIN content in the blood serum of patients with bone tumors did not reveal statistically significant differences between the control group and patients with borderline and malignant tumors, both in adults and in children. At the same time, a trend towards a decrease in the level of sEMMPRIN in the blood serum was noted in the presence of a malignant neoplasm of the bone compared with the corresponding control group. Additionally, we found that the content of sEMMPRIN is associated with age and higher in the group of patients under 18 years of age, both among healthy donors and oncological patients. An analysis of the association of sEMMPRIN content with clinical and morphological characteristics did not reveal statistically significant patterns, however, a trend towards an increase in the level of the marker with disease progression in both studied age groups was observed, which is consistent with other studies conducted on other solid tumors.Conclusion. ELISA revealed the marker sEMMPRIN in the blood serum of all examined children and adults with borderline malignant bone tumors and healthy donors. At the same time, the levels of sEMMPRIN did not differ between the above groups, however, there was a tendency for a decrease in the concentration of the marker in patients with bone sarcomas compared with the control group, regardless of age. |
| format | Article |
| id | doaj-art-e5a5401085ba4e098a71e484a7840114 |
| institution | DOAJ |
| issn | 2313-805X 2413-3787 |
| language | Russian |
| publishDate | 2023-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Успехи молекулярной онкологии |
| spelling | doaj-art-e5a5401085ba4e098a71e484a78401142025-08-20T03:00:54ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872023-07-0110210010710.17650/2313-805X-2023-10-2-100-107285The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the diseaseN. E. Kushlinskii0O. V. Kovaleva1Yu. B. Kuzmin2E. V. Samoilova3P. L. Prishchep4E. S. Gershtein5S. R. Varfolomeeva6D. V. Rogozhin7N. Yu. Sokolov8K. A. Borzov9E. A. Sushentsov10A. K. Valiev11I. S. Stilidy12N.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaN.N. Blokhin National Medical Russian Research Center of Oncology, Ministry of Health of RussiaIntroduction. Enzyme-linked immunosorbent assay of biochemical markers is one of the most important methods for diagnosing tumors. One of these markers is an inducer of expression of matrix metalloproteases EMMPRIN/CD147. Changes in its expression are associated with the progression of some tumors. This study is the first work devoted to the study of the content of the soluble form of the transmembrane glycoprotein EMMPRIN (sEMMPRIN) in the blood serum of patients with various bone tumors.Aim. To study the content of sEMMPRIN in the blood serum of patients with malignant bone tumors, its relationship with the clinical and morphological characteristics of neoplasms and prognosis.Materials and methods. The study included 88 patients with malignant tumors (osteosarcoma – 37 cases, chondrosarcoma – 39, chordoma – 5, Ewing’s sarcoma – 7) and borderline (11 cases) bone neoplasms, of which 14 patients were under the age of 18 years. The control group consisted of 29 healthy donors, 8 of which were under the age of 18 years. The concentration of EMMPRIN was determined in the serum of patients and donors with reagents for direct enzyme immunoassay “Human EMMPRIN” (R&D, USA) in accordance with the manufacturer’s instructions and expressed in nanograms (ng) per 1 ml of blood serum. The obtained data were processed using the GraphPad Prizm 9.4 program. When comparing indicators and analyzing their relationships, we used the nonparametric Mann–Whitney and Kruskal–Wallis tests. Overall survival was analyzed using the Kaplan–Meier method.Results. Our analysis of the sEMMPRIN content in the blood serum of patients with bone tumors did not reveal statistically significant differences between the control group and patients with borderline and malignant tumors, both in adults and in children. At the same time, a trend towards a decrease in the level of sEMMPRIN in the blood serum was noted in the presence of a malignant neoplasm of the bone compared with the corresponding control group. Additionally, we found that the content of sEMMPRIN is associated with age and higher in the group of patients under 18 years of age, both among healthy donors and oncological patients. An analysis of the association of sEMMPRIN content with clinical and morphological characteristics did not reveal statistically significant patterns, however, a trend towards an increase in the level of the marker with disease progression in both studied age groups was observed, which is consistent with other studies conducted on other solid tumors.Conclusion. ELISA revealed the marker sEMMPRIN in the blood serum of all examined children and adults with borderline malignant bone tumors and healthy donors. At the same time, the levels of sEMMPRIN did not differ between the above groups, however, there was a tendency for a decrease in the concentration of the marker in patients with bone sarcomas compared with the control group, regardless of age.https://umo.abvpress.ru/jour/article/view/545bone tumorssemmprin/cd147blood serum |
| spellingShingle | N. E. Kushlinskii O. V. Kovaleva Yu. B. Kuzmin E. V. Samoilova P. L. Prishchep E. S. Gershtein S. R. Varfolomeeva D. V. Rogozhin N. Yu. Sokolov K. A. Borzov E. A. Sushentsov A. K. Valiev I. S. Stilidy The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease Успехи молекулярной онкологии bone tumors semmprin/cd147 blood serum |
| title | The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease |
| title_full | The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease |
| title_fullStr | The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease |
| title_full_unstemmed | The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease |
| title_short | The content of sEMMPRIN/CD147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease |
| title_sort | content of semmprin cd147 in the blood serum of patients with bone tumors and its relationship with the clinical and morphological characteristics of the disease |
| topic | bone tumors semmprin/cd147 blood serum |
| url | https://umo.abvpress.ru/jour/article/view/545 |
| work_keys_str_mv | AT nekushlinskii thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT ovkovaleva thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT yubkuzmin thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT evsamoilova thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT plprishchep thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT esgershtein thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT srvarfolomeeva thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT dvrogozhin thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT nyusokolov thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT kaborzov thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT easushentsov thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT akvaliev thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT isstilidy thecontentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT nekushlinskii contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT ovkovaleva contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT yubkuzmin contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT evsamoilova contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT plprishchep contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT esgershtein contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT srvarfolomeeva contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT dvrogozhin contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT nyusokolov contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT kaborzov contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT easushentsov contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT akvaliev contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease AT isstilidy contentofsemmprincd147inthebloodserumofpatientswithbonetumorsanditsrelationshipwiththeclinicalandmorphologicalcharacteristicsofthedisease |